Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.48)
# 1,082
Out of 4,509 analysts
307
Total ratings
45.8%
Success rate
12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $88 | $59.31 | +48.37% | 10 | Jul 9, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $38 | $5.23 | +626.58% | 17 | Jul 7, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $6 | $1.38 | +334.78% | 12 | Jul 1, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $11.30 | +218.58% | 32 | Jun 30, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $27.88 | +57.82% | 15 | Jun 25, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $3.81 | +109.97% | 35 | Jun 17, 2026 | |
| PHAT Phathom Pharmaceuticals | Reiterated: Buy | $26 | $10.92 | +138.20% | 20 | Jun 17, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $14.64 | +50.27% | 15 | Jun 8, 2026 | |
| UPB Upstream Bio | Initiated Coverage: Buy | $36 | $7.28 | +394.51% | 1 | Jun 3, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $27.59 | +102.97% | 19 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $22.81 | +92.90% | 9 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $1.93 | +3.63% | 31 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $41.10 | +41.12% | 15 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $7.49 | +60.21% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $5.14 | +250.19% | 7 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $8 | $0.8586 | +831.75% | 12 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.02 | - | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.97 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $12.75 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $75.98 | n/a | 5 | Oct 21, 2022 |
Tarsus Pharmaceuticals
Jul 9, 2026
Reiterated: Buy
Price Target: $88
Current: $59.31
Upside: +48.37%
LENZ Therapeutics
Jul 7, 2026
Reiterated: Buy
Price Target: $38
Current: $5.23
Upside: +626.58%
Akebia Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $6
Current: $1.38
Upside: +334.78%
4D Molecular Therapeutics
Jun 30, 2026
Reiterated: Buy
Price Target: $36
Current: $11.30
Upside: +218.58%
Zenas BioPharma
Jun 25, 2026
Reiterated: Buy
Price Target: $44
Current: $27.88
Upside: +57.82%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $8
Current: $3.81
Upside: +109.97%
Phathom Pharmaceuticals
Jun 17, 2026
Reiterated: Buy
Price Target: $26
Current: $10.92
Upside: +138.20%
Immunic
Jun 8, 2026
Reiterated: Buy
Price Target: $22
Current: $14.64
Upside: +50.27%
Upstream Bio
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $7.28
Upside: +394.51%
Mineralys Therapeutics
Jun 1, 2026
Reiterated: Buy
Price Target: $56
Current: $27.59
Upside: +102.97%
May 26, 2026
Maintained: Buy
Price Target: $44
Current: $22.81
Upside: +92.90%
May 11, 2026
Reiterated: Hold
Price Target: $2
Current: $1.93
Upside: +3.63%
May 11, 2026
Reiterated: Buy
Price Target: $58
Current: $41.10
Upside: +41.12%
May 8, 2026
Reiterated: Buy
Price Target: $12
Current: $7.49
Upside: +60.21%
May 1, 2026
Reiterated: Buy
Price Target: $18
Current: $5.14
Upside: +250.19%
Apr 16, 2026
Maintained: Buy
Price Target: $80 → $8
Current: $0.8586
Upside: +831.75%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.02
Upside: -
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $2.97
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Maintained: Buy
Price Target: $39
Current: $12.75
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $75.98
Upside: n/a